Tempest Therapeutics, Inc. (TPST)
| Market Cap | 27.59M +1.0% |
| Revenue (ttm) | n/a |
| Net Income | -26.26M |
| EPS | -6.33 |
| Shares Out | 14.34M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,113 |
| Open | 1.937 |
| Previous Close | 1.920 |
| Day's Range | 1.875 - 2.025 |
| 52-Week Range | 1.500 - 12.230 |
| Beta | -1.68 |
| Analysts | Strong Buy |
| Price Target | 11.00 (+471.93%) |
| Earnings Date | May 26, 2026 |
About TPST
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for TPST stock is "Strong Buy" and the 12-month stock price target is $11.0.
News
Tempest Presents Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen rece...
Tempest to Advance Dual-Targeting CAR-T Platform with Clinical Update at ISCT 2026 Annual Meeting
BRISBANE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) will present its most recent clinical data from its lead dual-targeting chimeric antigen rece...
Tempest Therapeutics provides update on development of TPST-2003
Tempest Therapeutics (TPST) announced that it has achieved a milestone in the development of TPST-2003, Tempest’s dual-targeting CD19/BCMA CAR-T therapy under development for the treatment of relapsed...
Tempest Announces Key Manufacturing Milestone for TPST-2003 Dual-Targeting CD19/BCMA CAR-T
Delivery of TPST-2003 lentiviral vector to Cincinnati Children's Applied Gene and Cell Therapy Center enables manufacturing activities required for pivotal development Tech transfer on track to suppor...
Tempest Appoints Andrew Fang, Ph.D., as Head of Business Development to Advance Strategic Partnerships and Global Licensing Efforts
Adds dedicated business development leadership to support Tempest's strategic priorities Will lead China outreach and cross-border partnership efforts To support ongoing partnering discussions for Pha...
Tempest Therapeutics files to sell 2.78M shares of common stock for holders
06:07 EDT Tempest Therapeutics (TPST) files to sell 2.78M shares of common stock for holders
Tempest Therapeutics files to sell 8.27M shares of common stock for holders
18:00 EDT Tempest Therapeutics (TPST) files to sell 8.27M shares of common stock for holders
Tempest Reports Year End 2025 Financial Results and Provides Business Update
Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the ongoing...
Tempest Therapeutics Announces Up To $6 Million Private Placement
BRISBANE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (the “Company”), a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell ther...
Tempest, Cincinnati Children’s AGCTC partner for TPST-2003 registrational study
Tempest Therapeutics (TPST) announced the selection of Cincinnati Children’s Applied Gene and Cell Therapy Center as the lead contract development and manufacturing partner to conduct the formal techn...
Tempest Announces Partnership for TPST-2003 in Preparation for Planned U.S. Registrational Study in 2026
Cincinnati Children's Applied Gene and Cell Therapy Center selected to conduct tech transfer, development and IND-enabling manufacturing All activities other than long-term stability testing planned t...
Tempest Therapeutics announces data from REDEEM-1 Phase 1/2a trial on TPST-2003
Tempest Therapeutics (TPST) announced clinical data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, a CD19/BCMA dual-targeting CAR-T therapy. TPST-2003 is being developed in China by ...
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
BRISBANE, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced cell therapy and sma...
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and exter...
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets
BRISBANE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of advanced strategic therapeutic asse...
Tempest Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis upgraded Tempest Therapeutics (TPST) to Buy from Neutral with an $11 price target The company’s acquisition of Factor Bioscience’s CAR-T programs is a “shrewd ...
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders
BRISBANE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company with a pipeline of targeted and immune-mediated therap...
Tempest Therapeutics files to sell 1.17M shares of common stock for holders
16:53 EST Tempest Therapeutics (TPST) files to sell 1.17M shares of common stock for holders
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants $4.25 million upfront with up to an addi...
Tempest Therapeutics prices 1.17M shares at $3.63 in registered direct offering
Tempest Therapeutics (TPST) entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 1,172,414 shares of its common stock at an offering...
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated th...
Tempest announces acquisition of new dual-CAR T programs from Factor Bioscience
In a transaction designed to both expand its pipeline and extend its runway, Tempest Therapeutics (TPST) announced that it has entered into definitive agreements to acquire certain dual-targeting chim...
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027
All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and TPST-14...
Tempest Therapeutics reports Q3 EPS (79c) vs ($5.32) last year
“We are continuing our strategic alternatives process with the goal of maximizing value for stockholders,” said Stephen Brady, president and chief executive officer of Tempest. “In addition, we look f...
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update
BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class1 targeted and immune-mediated th...